Chronic myeloproliferative neoplasms in the elderly

Margherita Maffioli, Ester Orlandi, Francesco Passamonti

Research output: Contribution to journalArticlepeer-review


This review focuses on the management of elderly patients with chronic myeloid leukemia and chronic myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and primary myelofibrosis. Median age in these neoplasms is within the 6th decades of age. All new therapies can be done at any age without absolute contraindication. However, the selection of the precise therapy for the single patient is mandatory. For these reasons, an accurate definition of diagnosis and prognostication is necessary. Precision in disease definition and prognostication is definitively helpful for personalizing therapeutic approach.

Original languageEnglish
JournalEuropean Journal of Internal Medicine
Publication statusAccepted/In press - Jan 1 2018


  • Chronic myeloid leukemia
  • Myelofibrosis
  • Polycythemia
  • Thrombocythemia

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Chronic myeloproliferative neoplasms in the elderly'. Together they form a unique fingerprint.

Cite this